DEFM14A: Quanterix to Acquire Akoya Biosciences in All-Stock Merger

Quanterix Corporation will acquire Akoya Biosciences, Inc. in an all-stock transaction, pending stockholder and regulatory approvals.

Summary

• Quanterix Corporation, Akoya Biosciences, Inc., and Wellfleet Merger Sub, Inc. have entered into a definitive agreement for an all-stock merger.
• Merger Sub will merge with and into Akoya, with Akoya continuing as the surviving corporation and becoming a wholly owned subsidiary of Quanterix.
• Akoya stockholders will receive 0.318 shares of Quanterix Common Stock for each share of Akoya Common Stock they own.
• The Exchange Ratio will not be adjusted for changes in the market price of either Akoya Common Stock or Quanterix Common Stock between the date of signing of the Merger Agreement and consummation of the Merger.
• Based on the number of shares outstanding as of March 25, 2025, current Quanterix stockholders are expected to own approximately 70.99% of the combined company, and former Akoya stockholders are expected to own approximately 29.01%.
• The transaction is subject to stockholder and regulatory approvals and is expected to close in the second quarter of fiscal year 2025.
• Following the merger, Akoya Common Stock will be delisted from the Nasdaq Global Select Market.
• Quanterix will hold a special meeting of its stockholders, and Akoya will hold a special meeting of its stockholders to vote on the merger.
• The Quanterix Board recommends that Quanterix stockholders vote FOR the Quanterix Share Issuance Proposal.
• The Akoya Board unanimously recommends that Akoya stockholders vote FOR the Akoya Merger Proposal.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining the benefits of the merger and the recommendations of both boards. However, it also includes a detailed risk factors section, which tempers the overall sentiment.

Positives

• The merger is expected to create a stronger, more diversified company with a broader range of products and services.
• The combined company is expected to benefit from synergies and cost savings.
• Akoya stockholders will have the opportunity to participate in the potential upside of the combined company.
• The Quanterix Board believes that the Merger Agreement and the transactions contemplated thereby are fair to, and in the best interests of, Quanterix and its stockholders.

Negatives

• The value of the shares of Quanterix Common Stock received by Akoya stockholders in the Merger may differ from the implied value based on the share price on the date of signing of the Merger Agreement or the date of the joint proxy statement/prospectus.
• The Merger is subject to a number of conditions, and there is no guarantee that it will be completed.
• The integration of the two companies may be more difficult, costly, or time-consuming than expected.
• The Merger will dilute the ownership position of Quanterix stockholders.

Risks

• The Exchange Ratio is fixed and will not be adjusted in the event of any change in either Quanterixs or Akoyas stock price.
• The Merger may not be completed and the Merger Agreement may be terminated in accordance with its terms.
• The market price for shares of Quanterix Common Stock may be affected by factors different from, or in addition to, those that historically have affected or currently affect the market price of shares of Akoya Common Stock.
• Actions of activist or dissident stockholders could delay or prevent the approval of the Merger and negatively affect Quanterixs and Akoyas business and operations.
• The Share Issuance may cause the market price of Quanterix Common Stock to decline.
• Akoya stockholders who receive shares of Quanterix Common Stock in the Merger will have rights as Quanterix stockholders that differ from their current rights as Akoya stockholders.
• The Merger, and uncertainty regarding the Merger, may cause customers, service providers, partners, vendors, suppliers and other business relationships to delay or defer decisions concerning Quanterix or Akoya and adversely affect each companys ability to effectively manage its respective business, which could adversely affect each companys business, operating results and financial position and, following the completion of the Merger, the Combined Companys business, operating results and financial position.
• Whether or not the Merger is completed, the announcement and pendency of the Merger could cause disruptions in the businesses of Quanterix and Akoya, which could have an adverse effect on their respective businesses and financial results.
• Akoya and Quanterix directors and executive officers have interests and arrangements that may be different from, or in addition to, those of Akoya or Quanterix stockholders generally, respectively.
• The Merger Agreement contains provisions that could discourage a potential competing acquirer that might be willing to pay more to acquire or merge with either Quanterix or Akoya.
• Quanterix and Akoya expect to incur substantial costs related to the Merger and integration.
• Combining the businesses of Quanterix and Akoya may be more difficult, costly or time-consuming than expected and the Combined Company may fail to realize the anticipated benefits of the Merger, which may adversely affect the Combined Companys business results and negatively affect the value of Quanterixs Common Stock following completion of the Merger.
• The financial forecasts in this joint proxy statement/prospectus are based on various assumptions that may not be realized.

Future Outlook

The combined company expects to benefit from synergies and cost savings, and Akoya stockholders will have the opportunity to participate in the potential upside of the combined company.

Management Comments

• The Quanterix Board has determined that the Merger Agreement and the transactions contemplated thereby are fair to, and in the best interests of, Quanterix and its stockholders.
• The Akoya Board has determined that the Merger Agreement and the transactions contemplated by the Merger Agreement are fair to, and in the best interests of, Akoya and its stockholders.

Industry Context

The merger reflects a trend of consolidation in the life sciences industry, with companies seeking to expand their product offerings and reach a broader customer base.

Comparison to Industry Standards

• The document does not provide specific details on comparable companies or projects.
• The document does not provide specific details on global benchmarks.

Stakeholder Impact

• Akoya stockholders will receive shares of Quanterix Common Stock in the Merger.
• Quanterix stockholders will have their ownership diluted by the Share Issuance.
• The Combined Company will need to attract, motivate, and retain executives and other key employees.
• The Merger may cause customers, service providers, partners, vendors, suppliers and other business relationships to delay or defer decisions concerning Quanterix or Akoya.

Next Steps

• Quanterix and Akoya will hold special meetings of their stockholders to vote on the merger.
• The companies will seek regulatory approvals for the merger.
• The companies will work to complete the merger in the second quarter of fiscal year 2025.

Key Dates

Keywords

Merger, Acquisition, Quanterix, Akoya Biosciences, Stock Issuance, Shareholders, Biomarkers, Spatial Biology, Diagnostics